Umbralisib, a PI3Kδ/CK1ε dual inhibitor demonstrates marked clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: Results from the Phase 2 global UNITY-NHL trial

Drug Category: Array
Conference Category: Array
Lead Author: Zinzani P, et al.
Published Date: 07/12/2020
Download Link: /wp-content/uploads/2020/12/ASH2020ZinzaniPUNHL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top